IV Pain Medication for Acute Gout
For acute gout flares requiring IV therapy, use IV or intramuscular corticosteroids as the preferred option when oral medications cannot be administered. While guidelines primarily recommend oral agents (corticosteroids, NSAIDs, or colchicine), parenteral corticosteroids are the logical IV alternative when the oral route is unavailable 1.
Primary Recommendation
The 2017 American College of Physicians guideline strongly recommends corticosteroids, NSAIDs, or colchicine for acute gout treatment, with corticosteroids suggested as first-line therapy due to superior safety and equivalent efficacy 1. When IV administration is necessary:
- IV or IM corticosteroids are the evidence-based choice
- Prednisolone 35 mg orally for 5 days has proven efficacy, and parenteral equivalents can be used when oral route is not feasible 1
- Network meta-analysis data suggest IV/IM corticosteroids may be second only to canakinumab (a biologic) for pain reduction 2
Evidence Supporting Parenteral Corticosteroids
High-quality evidence demonstrates that systemic corticosteroids are as effective as NSAIDs for pain reduction but with fewer adverse effects 1, 3. Specifically:
- Corticosteroids showed equivalent pain reduction to NSAIDs at <7 days (SMD -0.09) and ≥7 days (SMD 0.32) 3
- Significantly lower risk of gastrointestinal adverse events: 50% reduction in indigestion, 75% reduction in nausea, and 89% reduction in vomiting compared to NSAIDs 3
- No evidence of increased bleeding risk (RR 0.09) 3
Why Not IV NSAIDs?
While NSAIDs are guideline-recommended for acute gout 1, IV NSAIDs (like ketorolac) are not specifically addressed in gout guidelines and carry significant cardiovascular and renal risks. Recent 2025 data shows NSAIDs increase MACE risk by 56% compared to colchicine in gout patients (HR 1.56), with particular increases in cardiovascular death (HR 2.50) 4. This makes IV corticosteroids the safer parenteral choice.
Alternative: Parenteral ACTH
Animal-derived corticotropin (ACTH) is a second-line parenteral option with moderate-quality evidence showing similar efficacy to NSAIDs and corticosteroids 1, 5. However, it has similar adverse effect profile to corticosteroids and is less commonly available 1.
What About IV Colchicine?
IV colchicine is strongly contraindicated due to severe toxicity and should never be used. Only oral low-dose colchicine (1.2 mg followed by 0.6 mg after 1 hour) is recommended 1.
Practical Approach
When oral medications cannot be given:
- First choice: IV methylprednisolone 40-60 mg or IM triamcinolone 40 mg
- Second choice: IM ACTH (if available)
- Avoid: IV NSAIDs (cardiovascular/renal risks), IV colchicine (toxic)
Important Caveats
- Corticosteroids are contraindicated in systemic fungal infections 1
- Short-term use (5-7 days) minimizes typical steroid adverse effects (dysphoria, hyperglycemia, immune suppression) 1
- Once patient can take oral medications, transition to oral corticosteroids, NSAIDs, or colchicine per standard guidelines 1
The 2020 ACR guideline focuses on urate-lowering therapy rather than acute flare management 6, so the 2017 ACP recommendations remain the most current high-quality guidance for acute treatment 1.